Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer

Yun, Sung Pil; Seo, Hyung Il

doi:10.1186/s12876-015-0396-x

Table 2 Univariate analysis for predictive factors influencing overall survival and disease-free survival after curative resection

From: Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer

Variables	N	5 years survival rate	Overall survival		5 years survival rate	Disease-free survival
Variables	N	5 years survival rate	Hazard ratio	P value	5 years survival rate	Hazard ratio	P value
Sex
Male	18	87.2	2.33 (0.45–12.05)	0.311	77.8	1.07 (0.28–3.99)	0.919
Female	19	68.0	2.33 (0.45–12.05)	0.311	73.7	1.07 (0.28–3.99)	0.919
Age, years
< 60	14	80.0	1.79 (0.34–9.21)	0.489	78.6	1.27 (0.32–5.09)	0.733
≥ 60	23	75.9	1.79 (0.34–9.21)	0.489	73.9	1.27 (0.32–5.09)	0.733
Subtype
Intestinal	17	93.3	8.45 (0.99–71.61)	0.051	94.1	8.34 (1.04–66.88)	0.046
Pancreaticobiliary	20	60.5	8.45 (0.99–71.61)	0.051	60.0	8.34 (1.04–66.88)	0.046
CK7 +/CK20 -
No	19	93.3	9.74 (1.16–81.89)	0.036	89.5	4.31 (0.89–20.77)	0.069
Yes	18	57.5	9.74 (1.16–81.89)	0.036	61.1	4.31 (0.89–20.77)	0.069
CDX2
No	20	75.2	1.26 (0.28–5.68)	0.764	75.0	1.02 (0.28–3.81)	0.972
Yes	16	79.3	1.26 (0.28–5.68)	0.764	75.0	1.02 (0.28–3.81)	0.972
T stage
T1, T2	22	95.2	13.94 (1.66–117.03)	0.015	95.5	14.81 (1.85–118.92)	0.011
T3, T4	15	45.4	13.94 (1.66–117.03)	0.015	46.7	14.81 (1.85–118.92)	0.011
Lymph node metastasis
No	31	88.4	6.00 (1.30–27.58)	0.021	83.9	5.69 (1.52–21.30)	0.010
Yes	6	33.3	6.00 (1.30–27.58)	0.021	33.3	5.69 (1.52–21.30)	0.010
Lymphovascular invasion
No	31	85.1	5.89 (1.27–27.38)	0.024	83.9	6.06 (1.58–23.28)	0.009
Yes	6	31.3	5.89 (1.27–27.38)	0.024	33.3	6.06 (1.58–23.28)	0.009
Perineural invasion
No	30	84.0	4.83 (1.07–21.87)	0.041	83.3	4.88 (1.29–18.40)	0.019
Yes	7	47.6	4.83 (1.07–21.87)	0.041	42.9	4.88 (1.29–18.40)	0.019
Size
< 2 cm	14	83.1	1.92 (0.37–9.94)	0.436	85.7	2.34 (0.49–11.25)	0.290
≥ 2 cm	23	73.8	1.92 (0.37–9.94)	0.436	69.6	2.34 (0.49–11.25)	0.290
Differentiation
Well/mod	31	86.0	8.18 (1.57–42.67)	0.013	87.1	12.29 (3.06–48.31)	<0.001
Poorly	6	0	8.18 (1.57–42.67)	0.013	16.7	12.29 (3.06–48.31)	<0.001
Stage
I and IIA	31	88.4	6.00 (1.30–27.58)	0.021	83.9	5.69 (1.52–21.30)	0.010
IIB and III	6	33.3	6.00 (1.30–27.58)	0.021	33.3	5.69 (1.52–21.30)	0.010
Ca19-9 (U/ml)
< 37	12	70.0	0.66 (0.13–3.28)	0.611	66.7	0.40 (0.09–1.81)	0.236
≥ 37	20	84.0	0.66 (0.13–3.28)	0.611	85.0	0.40 (0.09–1.81)	0.236
CEA (ng/ml)
< 5	27	83.2	1.28 (0.14–11.54)	0.826	81.5	1.37 (0.16–11.74)	0.774
≥ 5	4	75.0	1.28 (0.14–11.54)	0.826	75.0	1.37 (0.16–11.74)	0.774
Pancreatic fistula
No	21	77.2	0.88 (0.20–3.95)	0.872	71.4	0.59 (0.15–2.35)	0.453
Yes	16	77.9	0.88 (0.20–3.95)	0.872	81.3	0.59 (0.15–2.35)	0.453
Adjuvant therapy
No	20	90.0	3.67 (0.70–19.02)	0.122	90.0	5.11 (1.06–24.68)	0.042
Yes	17	58.2	3.67 (0.70–19.02)	0.122	58.8	5.11 (1.06–24.68)	0.042

CK7 Cytokeratin 7, CK20 Cytokeratin 20, CA19-9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen

Back to article page

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Gastroenterology

Contact us